Pauline Bosco-Lévy

Pauline Bosco-Lévy

Auto-generated profile, based on publicly available information

Pauline Bosco-Lévy

Université de Bordeaux, Inserm CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
PBPauline Bosco‐Lévy
Pauline Bosco‐Lévy
SDStéphanie Duret
Stéphanie Duret
FPFrançois Picard
François Picard
PSPierre Dos Santos
Pierre Dos Santos
EPEtienne Puymirat
Etienne Puymirat
NMNicholas Moore
Nicholas Moore

2 August 2021 in Drug Safety
Verified
Journal Article
Closed access
PDF file
NMNicholas Moore
Nicholas Moore
PBPauline Bosco-Levy
Pauline Bosco-Levy
Nicolas H ThurinNicolas H Thurin
Nicolas H Thurin
PBPatrick Blin
Patrick Blin
CDCécile Droz-Perroteau
Cécile Droz-Perroteau

22 December 2021 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
PBPauline Bosco‐Lévy
Pauline Bosco‐Lévy
CFCaroline Foch
Caroline Foch
AGAngela Grelaud
Angela Grelaud
MSMeritxell Sabidó
Meritxell Sabidó
CLClémentine Lacueille
Clémentine Lacueille
PBPatrick Blin
Patrick Blin

6 September 2016 in British Journal of Cancer
Verified
Journal Article
Open access
PBPauline Bosco-Lévy
Pauline Bosco-Lévy
JJJeremy Jové
Jeremy Jové
PRPhilip Robinson
Philip Robinson
NMNicholas Moore
Nicholas Moore
AFAnnie Fourrier-Réglat
Annie Fourrier-Réglat
JBJulien Bezin
Julien Bezin
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

3 August 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
PBPauline Bosco‐Lévy
Pauline Bosco‐Lévy
PBPaul de Boissieu
Paul de Boissieu
AGAmandine Gouverneur
Amandine Gouverneur
PNPernelle Noize
Pernelle Noize
MMMathieu Molimard
Mathieu Molimard
JBJulien Bezin
Julien Bezin

1 May 2021 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
Nicolas H ThurinNicolas H Thurin
Nicolas H Thurin
PBPauline Bosco-Levy
Pauline Bosco-Levy
PBPatrick Blin
Patrick Blin
MRMagali Rouyer
Magali Rouyer
JJJérémy Jové
Jérémy Jové
CDCécile Droz-Perroteau
Cécile Droz-Perroteau
Background: Diagnosis performances of case-identifying algorithms developed in healthcare database are usually assessed by comparing identified cases with an external data source. When this is not feasible, intra-database validation can present an appropriate alternative. Objectives: To illustrate through two practical examples how to perform intra-database validations of case-identifying algorithms using reconstituted Electronic Health Records (rEHRs). Methods: Patients with 1) multiple sclerosis (MS) relapses and 2) metastatic castration-resistant prostate cancer (mCRPC) were identified in the French nationwide healthcare database (SNDS) using two case-identifying algorithms. A validation study was then conducted to estimate diagnostic performances of these algorithms through the calculation of their positive predictive value (PPV) and negative predictive value (NPV). To that end, anonymized rEHRs were generated based on the overall information captured in the SNDS over time (e.g. procedure, hospital stays, drug dispensing, medical visits) for a random selection of patients identified as cases or non-cases according to the predefined algorithms. For each disease, an independent validation committee reviewed the rEHRs of 100 cases and 100 non-cases in order to adjudicate on the status of the selected patients (true case/ true non-case), blinded with respect to the result of the corresponding algorithm. Results: Algorithm for relapses identification in MS showed a 95% PPV and 100% NPV. Algorithm for mCRPC identification showed a 97% PPV and 99% NPV. Conclusion: The use of rEHRs to conduct an intra-database validation appears to be a valuable tool to estimate the performances of a case-identifying algorithm and assess its validity, in the absence of alternative.